Literature DB >> 32583237

Melatonin: an endogenous miraculous indolamine, fights against cancer progression.

Saptadip Samanta1.   

Abstract

PURPOSE: Melatonin is an amphipathic indolamine molecule ubiquitously present in all organisms ranging from cyanobacteria to humans. The pineal gland is the site of melatonin synthesis and secretion under the influence of the retinohypothalamic tract. Some extrapineal tissues (skin, lens, gastrointestinal tract, testis, ovary, lymphocytes, and astrocytes) also enable to produce melatonin. Physiologically, melatonin regulates various functions like circadian rhythm, sleep-wake cycle, gonadal activity, redox homeostasis, neuroprotection, immune-modulation, and anticancer effects in the body. Inappropriate melatonin secretion advances the aging process, tumorigenesis, visceral adiposity, etc.
METHODS: For the preparation of this review, I had reviewed the literature on the multidimensional activities of melatonin from the NCBI website database PubMed, Springer Nature, Science Direct (Elsevier), Wiley Online ResearchGate, and Google Scholar databases to search relevant articles. Specifically, I focused on the roles and mechanisms of action of melatonin in cancer prevention.
RESULTS: The actions of melatonin are primarily mediated by G-protein coupled MT1 and MT2 receptors; however, several intracellular protein and nuclear receptors can modulate the activity. Normal levels of the melatonin protect the cells from adverse effects including carcinogenesis. Therapeutically, melatonin has chronomedicinal value; it also shows a remarkable anticancer property. The oncostatic action of melatonin is multidimensional, associated with the advancement of apoptosis, the arrest of the cell cycle, inhibition of metastasis, and antioxidant activity.
CONCLUSION: The present review has emphasized the mechanism of the anti-neoplastic activity of melatonin that increases the possibilities of the new approaches in cancer therapy.

Entities:  

Keywords:  Anti-metastatic; Anti-proliferative; Anticancer; Antioxidant; Melatonin; Suprachiasmatic nucleus

Year:  2020        PMID: 32583237     DOI: 10.1007/s00432-020-03292-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  5 in total

Review 1.  Revisiting the role of melatonin in human melanocyte physiology: A skin context perspective.

Authors:  Alec Sevilla; Jérémy Chéret; Radomir M Slominski; Andrzej T Slominski; Ralf Paus
Journal:  J Pineal Res       Date:  2022-04       Impact factor: 13.007

2.  Melatonin Reverses the Warburg-Type Metabolism and Reduces Mitochondrial Membrane Potential of Ovarian Cancer Cells Independent of MT1 Receptor Activation.

Authors:  Maira Smaniotto Cucielo; Roberta Carvalho Cesário; Henrique Spaulonci Silveira; Letícia Barbosa Gaiotte; Sérgio Alexandre Alcantara Dos Santos; Debora Aparecida Pires de Campos Zuccari; Fábio Rodrigues Ferreira Seiva; Russel J Reiter; Luiz Gustavo de Almeida Chuffa
Journal:  Molecules       Date:  2022-07-07       Impact factor: 4.927

3.  The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.

Authors:  Jiafei Wu; Xiao Tan
Journal:  Int J Cancer       Date:  2022-05-09       Impact factor: 7.316

4.  Melatonin Inhibits Migration and Invasion in LPS-Stimulated and -Unstimulated Prostate Cancer Cells Through Blocking Multiple EMT-Relative Pathways.

Authors:  Qi-Xing Tian; Zhi-Hui Zhang; Qing-Lin Ye; Shen Xu; Qian Hong; Wei-Yang Xing; Lei Chen; De-Xin Yu; De-Xiang Xu; Dong-Dong Xie
Journal:  J Inflamm Res       Date:  2021-05-25

5.  Effects of melatonin and metformin in preventing lysosome-induced autophagy and oxidative stress in rat models of carcinogenesis and the impact of high-fat diet.

Authors:  Natalia Kurhaluk; Halyna Tkachenko
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.